Company / Shareholders' Equity
Mirum Pharmaceuticals, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$314.7M
FY2025
5-year range
$172.1M / $314.7M
FY2021-FY2025
Trend
+39.5%
vs FY2024
Sector context
#126 of 213
Health Care
What the data says
At $315M, Mirum Pharmaceuticals, Inc.'s shareholders' equity ranks #126 of 213 in the Health Care sector. Improved from $249M to $315M over the past 2 years.
Based on SEC 10-K filings.
$315M in FY2025 with a 5-year CAGR of +12.8%.
Improved from $249M to $315M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +22.3%
- 5-Year CAGR
- +12.8%
- 10-Year CAGR
- -
Sector benchmark
#126 of 213 in Health CareTop 59% of 213This company $314.7M Sector average $2.5B
▼
-87.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +12.8%, indicating consistent growth.
- In FY2025, shareholders' equity increased 39.5% year-over-year.
- Ranks #126 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -26.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $314.7M | +39.5% |
| FY2024 | $225.6M | -9.3% |
| FY2023 | $248.7M | +44.5% |
| FY2022 | $172.1M | +0.0% |
| FY2021 | $172.1M | +0.0% |
| FY2020 | $172.1M | +32.0% |
| FY2019 | $130.3M | +852.9% |
| FY2018 | -$17.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026